Samadi N, Klems M, Heiden D, Bauer R, Kitzmüller C, Weidmann E, Ret D, Ondracek AS, Duschl A, Horejs-Hoeck J, Untersmayr E. Allergy. 2019 Aug 24. doi: 10.1111/all.14030. PMID: 31444907
Samadi N, Polak D, Kitzmüller C, Steinberger P, Zlabinger GJ, Jahn-Schmid B, Bohle B.
Eur J Immunol. 2019. doi: 10.1002/eji.201848057. PMID: 31332790
July 30, 2019, Nature Communications 10, 3298, by Jordakieva et al.: Antiacids drugs prime subsequent anti-allergy prescriptions.
30% of 30-years old, and 33% of 60-year old Austrians are treated with gastric acid-inhibitors. As a continuation of their previous works, the team around Erika Jensen-Jarolim performed a population-wide study in Austria and found a significant correlation between the intake of these drugs and symptoms of respiratory allergies, treated by H1R blockers and allergen-specific immunotherapy. See https://www.nature.com/articles/s41467-019-10914-6
Sublingual immunotherapy with recombinant Mal d 1 downregulates the allergen-specific Th2 response.
Kitzmüller C, Jahn-Schmid B, Kinaciyan T, Bohle B.
Allergy. 2019 Aug;74(8):1579-1581. doi: 10.1111/all.13779. Epub 2019 Apr 10.
A study published in Computational and Structural Biotechnology Journal and conducted by Anastasia Meshcheryakova from the Systems Biology and Pathophysiology Group of Diana Mechtcheriakova together with colleagues from the Medical University of Vienna and the multidisciplinary team of international experts made an effort to look from another angle on potential therapeutic checkpoints for epithelial ovarian cancer and propose that assessment of the sphingolipid and lysophosphatidate systems in conjunction with the local immune response may lead to novel stratifying and targeting strategies. This offers the power for improving the efficacy of existing therapies and possibly immunotherapies.